Zhejiang Medicine Co., Ltd. Sustainability Profile
Zhejiang Medicine Co., Ltd., commonly referred to as ZMC, is a prominent player in the pharmaceutical industry, headquartered in China. Established in 1995, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across various regions, ZMC is dedicated to innovation and quality, offering unique formulations that cater to both domestic and international markets. The company has achieved notable milestones, including certifications that underscore its commitment to excellence in manufacturing practices. Renowned for its robust portfolio, ZMC continues to solidify its market position through strategic partnerships and a focus on research and development, making it a key contributor to the global healthcare landscape.
DitchCarbon Score
How does Zhejiang Medicine Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zhejiang Medicine Co., Ltd.'s score of 20 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zhejiang Medicine Co., Ltd.'s reported carbon emissions
Zhejiang Medicine Co., Ltd., headquartered in China, currently does not report any specific carbon emissions data, as indicated by the absence of figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how Zhejiang Medicine Co., Ltd. aligns with industry standards for climate action. The absence of specific targets or commitments may reflect a broader trend within the pharmaceutical sector, where companies are increasingly being called upon to disclose their environmental impact and set ambitious goals for emissions reduction. In summary, without available emissions data or climate commitments, Zhejiang Medicine Co., Ltd. appears to have limited engagement in carbon management and sustainability initiatives.
How Carbon Intensive is Zhejiang Medicine Co., Ltd.'s Industry?
How Carbon Intensive is Zhejiang Medicine Co., Ltd.'s Location?
Zhejiang Medicine Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zhejiang Medicine Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
